Congress of Neurological Surgeons Systematic Review and Evidence-based Guidelines Update on the Role of Neuropathology in the Management of Progressive Glioblastoma in Adults

Overview

Journal J Neurooncol

Publisher Springer

Date 2022 Jun 1

PMID 35648306

Authors

Abigail L Goodman

Jose E Velazquez Vega

Chad Glenn

Jeffrey J Olson

Affiliations

Soon will be listed here.

Abstract

Target Population: These recommendations apply to adult patients with progressive or recurrent glioblastoma (GBM).

Question: For adult patients with progressive glioblastoma are there meaningful biomarkers for bevacizumab responsiveness and does their assessment provide additional information for tumor management and prognosis beyond that learned by standard histologic analysis?

Recommendation: Level III: No established Bevacizumab biomarkers are currently available based upon the inclusion criteria of this guideline.

References

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Choi S, Shin H, Sa J, Cho H, Koo H, Kong D . Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. Cancer Med. 2018; 7(5):1774-1783. PMC: 5943425. DOI: 10.1002/cam4.1439. View

Bagley S, Schwab R, Nelson E, Viaene A, Binder Z, Lustig R . Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma. J Neurooncol. 2018; 141(2):421-429. DOI: 10.1007/s11060-018-03050-6. View

Weller M, Cloughesy T, Perry J, Wick W . Standards of care for treatment of recurrent glioblastoma--are we there yet?. Neuro Oncol. 2012; 15(1):4-27. PMC: 3534423. DOI: 10.1093/neuonc/nos273. View

Montemurro N, Perrini P, Olivares Blanco M, Vannozzi R . Second surgery for recurrent glioblastoma: A concise overview of the current literature. Clin Neurol Neurosurg. 2016; 142:60-64. DOI: 10.1016/j.clineuro.2016.01.010. View

Brat D, Ryken T, Kalkanis S, Olson J . The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014; 118(3):461-78. DOI: 10.1007/s11060-013-1331-z. View

Hu L, Eschbacher J, Heiserman J, Dueck A, Shapiro W, Liu S . Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol. 2012; 14(7):919-30. PMC: 3379799. DOI: 10.1093/neuonc/nos112. View

Burger P, Nelson J, Boyko O . Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. Arch Pathol Lab Med. 1998; 122(7):620-32. View

10.

Olson J, Fadul C, Brat D, Mukundan S, Ryken T . Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol. 2009; 93(1):1-23. DOI: 10.1007/s11060-009-9838-z. View

11.

Holdhoff M, Ye X, Piotrowski A, Strowd R, Seopaul S, Lu Y . The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma. J Neurooncol. 2018; 141(2):347-354. PMC: 6342857. DOI: 10.1007/s11060-018-03037-3. View

12.

Azoulay M, Santos F, Shenouda G, Petrecca K, Oweida A, Guiot M . Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. J Neurooncol. 2017; 132(3):419-426. DOI: 10.1007/s11060-017-2383-2. View

13.

Woodworth G, Garzon-Muvdi T, Ye X, Blakeley J, Weingart J, Burger P . Histopathological correlates with survival in reoperated glioblastomas. J Neurooncol. 2013; 113(3):485-93. PMC: 3994532. DOI: 10.1007/s11060-013-1141-3. View

14.

Okita Y, Narita Y, Miyakita Y, Ohno M, Fukushima S, Kayama T . Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 2012; 29(4):192-200. DOI: 10.1007/s10014-012-0084-2. View

15.

Brat D, Aldape K, Colman H, Holland E, Louis D, Jenkins R . cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol. 2018; 136(5):805-810. PMC: 6204285. DOI: 10.1007/s00401-018-1913-0. View

16.

Brat D, Aldape K, Colman H, Figrarella-Branger D, Fuller G, Giannini C . cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020; 139(3):603-608. PMC: 8443062. DOI: 10.1007/s00401-020-02127-9. View

17.

Pisapia D . The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas. Arch Pathol Lab Med. 2017; 141(12):1633-1645. DOI: 10.5858/arpa.2016-0493-RA. View

18.

Cohen M, Shen Y, Keegan P, Pazdur R . FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14(11):1131-8. DOI: 10.1634/theoncologist.2009-0121. View

19.

Millward C, Brodbelt A, Haylock B, Zakaria R, Baborie A, Crooks D . The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir (Wien). 2016; 158(10):1943-53. DOI: 10.1007/s00701-016-2928-8. View

20.

Johnson B, Mazor T, Hong C, Barnes M, Aihara K, McLean C . Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2013; 343(6167):189-193. PMC: 3998672. DOI: 10.1126/science.1239947. View